Molecular Diagnostics Platforms: Complete Guide to PCR, Digital PCR, NGS, Automation, Performance & Platform Selection
Modern molecular laboratories may use real-time PCR, multiplex PCR, digital PCR, isothermal amplification, targeted sequencing, whole-exome sequencing, whole-genome sequencing, long-read sequencing, automated nucleic-acid extraction and integrated sample-to-answer systems.
This guide explains the major molecular diagnostics platforms, how they work, where they fit in the laboratory, their strengths and limitations, and how laboratories should evaluate a molecular platform before purchase or implementation.
1. What Are Molecular Diagnostics Platforms?
Molecular diagnostics platforms are laboratory technologies used to detect, quantify, characterize or sequence nucleic acids such as DNA and RNA.
They can be used to identify:
- Pathogens
- Genetic variants
- Mutations
- Gene fusions
- Copy-number changes
- Inherited disease-associated variants
- Oncogenic alterations
- Drug-resistance markers
- Pharmacogenomic variants
- Microbial genetic signatures
- Other clinically relevant molecular biomarkers
The U.S. FDA describes in-vitro diagnostics as tests performed on specimens obtained from the human body and notes that molecular IVDs can be used in areas including precision medicine.
2. Molecular Diagnostics Is a Workflow, Not Just an Analyzer
One of the biggest mistakes in molecular laboratory planning is focusing only on the amplification or sequencing instrument.
Every stage can influence the final result.
| Stage | Major considerations |
|---|---|
| Specimen collection | Specimen type, volume, transport, storage and stability |
| Sample preparation | Lysis, purification and removal of inhibitors |
| Nucleic-acid extraction | Yield, purity, integrity and reproducibility |
| Target amplification | Primers, probes, amplification efficiency and specificity |
| Sequencing | Library preparation, sequencing chemistry, read quality and depth |
| Detection | Fluorescence, electrical, optical or sequencing signal |
| Bioinformatics | Alignment, variant calling, annotation and filtering |
| Interpretation | Clinical significance and reporting criteria |
| Reporting | Result verification, LIS integration and clinical report |
3. Major Molecular Diagnostics Platform Categories
| Platform | Primary principle | Typical applications |
|---|---|---|
| Conventional PCR | Thermal cycling + endpoint detection | Research, genotyping, amplification |
| Real-time PCR / qPCR | Amplification monitored during cycling | Pathogen detection, viral load, gene expression |
| Multiplex PCR | Multiple targets amplified simultaneously | Respiratory, GI, STI and other panels |
| Digital PCR | Partitioned reactions + endpoint counting | Low-level variants, copy number, rare targets |
| Isothermal amplification | Amplification at approximately constant temperature | Rapid and decentralized molecular testing |
| NGS | Massively parallel sequencing | Genomics, oncology, infectious disease and inherited disorders |
| Long-read sequencing | Long DNA/RNA molecule sequencing | Structural variants, repetitive regions and genome characterization |
| Automated extraction | Automated nucleic-acid purification | High-throughput molecular laboratories |
| Sample-to-answer systems | Integrated preparation + amplification + detection | Rapid clinical molecular diagnostics |
4. Conventional PCR
Conventional polymerase chain reaction is one of the foundational molecular techniques.
The basic process consists of repeated cycles of:
- Denaturation
- Primer annealing
- Extension
The amplified product is generally detected after the reaction, traditionally using gel electrophoresis or another endpoint method.
Advantages
- Well-established technology
- Relatively straightforward workflow
- Useful for targeted amplification
- Can be economical for selected applications
Limitations
- Usually requires post-amplification handling
- Lower automation potential than closed real-time systems
- Greater contamination risk when amplified products are opened
- Limited quantitative capability
5. Real-Time PCR / qPCR
Real-time PCR measures amplification as it occurs rather than waiting until the end of the reaction.
Fluorescence generated during amplification is monitored cycle by cycle.
Depending on the assay design, the system may use:
- DNA-binding fluorescent dyes
- Sequence-specific hydrolysis probes
- Other fluorescence-based probe chemistries
Why qPCR became so important
Real-time PCR provides a closed analytical workflow with rapid detection and, when appropriately calibrated and designed, quantitative information.
It is widely used for:
- Pathogen detection
- Viral nucleic-acid quantification
- Genotyping
- Mutation detection
- Gene-expression studies
- Research applications
6. Understanding Ct / Cq
In many real-time PCR assays, the cycle threshold or quantification cycle is related to the point at which fluorescence becomes distinguishable from background.
In general, a sample containing more amplifiable target may cross the detection threshold earlier than a sample containing less target.
7. Multiplex PCR
Multiplex PCR allows several targets to be detected within a single reaction.
This can substantially improve workflow efficiency because one specimen can be tested for multiple pathogens or molecular targets simultaneously.
Examples include multiplex panels for:
- Respiratory pathogens
- Gastrointestinal pathogens
- Sexually transmitted infections
- Central nervous system infections
- Sepsis-related organisms
- Drug-resistance targets
The challenge of multiplexing
Multiplexing is not simply a matter of adding more primers.
Increasing the number of targets can introduce:
- Primer competition
- Non-specific amplification
- Signal overlap
- Different amplification efficiencies
- Complex interpretation
- More complicated quality-control requirements
8. Digital PCR
Digital PCR takes a different approach from conventional quantitative PCR.
The reaction mixture is divided into a large number of partitions. After amplification, partitions are classified as positive or negative for the target. Statistical analysis can then estimate the target concentration.
Partition → Amplify → Count positive/negative partitions → Statistical estimation
Digital PCR can be particularly valuable where highly sensitive detection or precise quantification is required.
Potential applications
- Rare mutation detection
- Low-level residual disease applications
- Copy-number analysis
- Low-abundance targets
- Viral nucleic-acid quantification
- Reference-material characterization
- Research applications
Commercial molecular diagnostics portfolios now include qPCR, digital PCR and NGS technologies, illustrating how these platforms can occupy different positions within the molecular testing ecosystem.
9. qPCR vs Digital PCR
| Feature | qPCR | Digital PCR |
|---|---|---|
| Measurement | Real-time fluorescence kinetics | Endpoint partition classification |
| Output | Relative or calibrated quantitative result | Partition-based absolute quantification |
| Sensitivity | High | Can be particularly advantageous for low-abundance targets |
| Dynamic workflow | Highly established | More specialized |
| Multiplexing | Widely available | Platform dependent |
| Cost/sample | Generally lower | Generally higher |
| Best fit | Routine molecular testing | Selected high-sensitivity/precision applications |
10. Isothermal Amplification
Unlike PCR, which repeatedly changes temperature, isothermal amplification technologies amplify nucleic acids at a relatively constant temperature.
Examples include:
- LAMP
- RPA
- TMA
- Other constant-temperature amplification approaches
Their potential advantages include simpler thermal requirements and rapid amplification, although each technology has its own analytical characteristics and limitations.
11. Sample-to-Answer Molecular Platforms
One of the most important developments in clinical molecular diagnostics is the integration of multiple analytical steps into a single system.
The operator may simply load the specimen and consumable while the instrument performs most of the analytical workflow.
Advantages
- Reduced hands-on time
- Lower opportunity for contamination
- Standardized workflow
- Rapid turnaround
- Potentially simpler training
- Reduced manual pipetting
Limitations
- Higher consumable cost
- Limited flexibility
- Vendor dependency
- Closed-cartridge limitations
- Potentially limited assay menu
12. Open vs Closed Molecular Platforms
| Feature | Open system | Closed system |
|---|---|---|
| Assay flexibility | High | Usually lower |
| Vendor dependence | Lower | Higher |
| Workflow simplicity | More complex | Generally simpler |
| Customization | High potential | Limited |
| Contamination control | Depends heavily on workflow | Often better controlled |
| Initial implementation | More demanding | Usually easier |
13. Nucleic-Acid Extraction Systems
Extraction is often the hidden determinant of molecular-test performance.
A highly sophisticated PCR or sequencing instrument cannot compensate for poor nucleic-acid extraction.
Extraction systems may perform:
- Cell lysis
- Protein removal
- Nucleic-acid binding
- Washing
- Elution
- Internal-control addition
Common extraction approaches include silica-based methods, magnetic-bead purification and other chemistry-specific methods.
14. Why Extraction Quality Matters
Molecular specimens can contain substances that inhibit amplification or interfere with downstream reactions.
Examples include:
- Hemoglobin
- Heparin
- Salts
- Phenolic compounds
- Proteins
- Other specimen-specific inhibitors
Therefore, a molecular platform evaluation should include not only analytical sensitivity but also extraction robustness across real clinical specimens.
15. Internal Controls
Internal controls are particularly important in molecular diagnostics because a negative result may arise from either true absence of target or analytical failure.
An internal control may help monitor:
- Extraction
- Amplification
- Detection
- Inhibition
- Sample adequacy
16. External Controls
External positive and negative controls help monitor the analytical process.
A molecular QC program may include:
- Positive control
- Negative control
- No-template control where appropriate
- Internal amplification control
- Extraction control
- External quality assessment/proficiency testing
The exact control strategy should reflect the assay design, platform and applicable laboratory requirements.
17. Contamination Control
Molecular laboratories face a distinctive risk: amplified nucleic acid can become a source of contamination.
Good molecular workflow design therefore considers:
- Unidirectional workflow
- Physical separation of pre- and post-amplification areas
- Dedicated equipment
- Appropriate PPE
- Controlled movement of materials
- Decontamination procedures
- Closed-tube systems where appropriate
18. NGS — Next-Generation Sequencing
Next-generation sequencing allows large numbers of nucleic-acid molecules to be sequenced in parallel.
Unlike a targeted PCR assay that asks a relatively specific question, NGS can interrogate many genomic regions simultaneously.
The FDA notes that NGS tests can identify or sequence large sections of the genome and are increasingly relevant to precision medicine.
19. Targeted NGS
Targeted sequencing focuses on selected genes or genomic regions.
Target enrichment may involve:
- Amplicon-based approaches
- Hybrid-capture approaches
- Other enrichment strategies
Targeted panels can be attractive in clinical diagnostics because they concentrate sequencing resources on clinically relevant regions.
Applications include:
- Oncology panels
- Inherited disease panels
- Pharmacogenomics
- Cardiovascular genetics
- Neurological genetics
- Infectious disease panels
20. Whole-Exome Sequencing
Whole-exome sequencing focuses primarily on protein-coding regions of the genome.
It can provide broader genomic interrogation than a small targeted panel while generally being more focused than whole-genome sequencing.
It can be useful in selected inherited-disease and research workflows.
21. Whole-Genome Sequencing
Whole-genome sequencing aims to interrogate genomic DNA across essentially the entire genome rather than limiting the analysis to selected genes.
Potential advantages include broader variant discovery and the ability to investigate regions outside conventional targeted panels.
However, broader data generation also creates greater requirements for:
- Data storage
- Bioinformatics
- Variant filtering
- Interpretation
- Clinical annotation
- Quality control
22. Short-Read vs Long-Read Sequencing
| Feature | Short-read sequencing | Long-read sequencing |
|---|---|---|
| Read length | Shorter individual reads | Much longer individual reads |
| Strength | High-throughput accurate sequencing for many applications | Long-range genomic structure |
| Structural variants | May require specialized approaches | Can be particularly advantageous |
| Repeat regions | Can be challenging | Long reads can span some repetitive regions |
| Data analysis | Highly established workflows | Different computational requirements |
The choice depends on the biological question rather than simply the newest sequencing technology.
23. What Is Library Preparation?
In NGS, library preparation converts DNA or RNA-derived material into molecules suitable for sequencing.
Depending on the platform and assay, library preparation can include:
- Fragmentation
- End repair
- Adapter ligation
- Amplification
- Target enrichment
- Index/barcode incorporation
- Purification
Library preparation can become a major source of hands-on time and variability.
24. NGS Sequencing Chemistry
Different sequencing platforms use different physical and chemical approaches to detect nucleotide incorporation.
Examples include:
- Sequencing by synthesis
- Ion-based detection
- Single-molecule sequencing
- Other emerging sequencing approaches
For example, Illumina's sequencing-by-synthesis approach detects nucleotide incorporation through sequential imaging of sequencing clusters.
25. NGS Is Not Just a Sequencer
This is perhaps the most important concept when comparing NGS platforms.
A sequencing instrument can produce excellent raw data while the overall clinical workflow still fails because of inadequate sample preparation, poor library quality, inappropriate bioinformatics or weak interpretation.
The FDA's NGS framework explicitly recognizes that the workflow extends through specimen preparation, sequencing/data collection, data analysis and reporting.
26. Bioinformatics Is Part of the Diagnostic Platform
For NGS-based diagnostics, software and bioinformatics are not optional accessories.
They may perform:
- Quality assessment
- Demultiplexing
- Alignment
- Variant calling
- Variant filtering
- Annotation
- Coverage analysis
- Quality scoring
- Database comparison
- Clinical interpretation support
The FDA has highlighted the importance of bioinformatics, public databases and standards in supporting reliable NGS-based testing.
27. Understanding NGS Coverage
Coverage describes how many sequencing reads support a particular genomic position.
High average coverage does not automatically mean that every clinically relevant position is adequately covered.
Laboratories should therefore evaluate:
- Mean coverage
- Minimum coverage
- Percentage of target bases above the required threshold
- Uniformity
- Regions with poor coverage
- GC-rich regions
- Homopolymer or repetitive regions
28. Variant Detection Is Not the Same as Variant Interpretation
A molecular platform may detect a sequence alteration, but determining its clinical significance is a separate step.
Variant interpretation may require:
- Population databases
- Clinical databases
- Literature
- Functional evidence
- Inheritance information
- Phenotypic correlation
- Established classification criteria
29. Molecular Diagnostic Applications
| Application | Potential molecular technologies |
|---|---|
| Infectious diseases | PCR, multiplex PCR, RT-PCR, targeted sequencing, NGS |
| Oncology | qPCR, dPCR, targeted NGS, liquid biopsy sequencing |
| Inherited disorders | Targeted panels, WES, WGS |
| Pharmacogenomics | PCR, genotyping, targeted NGS |
| Reproductive genetics | PCR, microarray, targeted sequencing, NGS |
| Hematological malignancies | qPCR, dPCR, targeted NGS |
| Rare diseases | Targeted panels, WES, WGS |
| Transplant monitoring | PCR/dPCR and selected sequencing approaches |
30. Molecular Oncology Platforms
Oncology is one of the most technically demanding applications of molecular diagnostics.
Testing may investigate:
- Single nucleotide variants
- Insertions/deletions
- Copy-number alterations
- Gene fusions
- Structural variants
- Microsatellite instability
- Tumor mutational burden
- Other genomic biomarkers
Modern oncology NGS systems may combine target enrichment, sequencing instrumentation, software and bioinformatics into a single diagnostic workflow. FDA device classifications for NGS oncology systems reflect this integrated architecture.
31. Liquid Biopsy and Cell-Free DNA
Cell-free DNA and circulating tumor DNA have created new opportunities for molecular testing from plasma.
However, these applications can involve extremely low target fractions.
Important analytical considerations include:
- Plasma volume
- DNA extraction efficiency
- DNA integrity
- Background DNA
- Variant allele fraction
- Analytical sensitivity
- False-positive suppression
- Sequencing depth
This is an area where highly sensitive PCR/dPCR and NGS approaches can serve different but complementary roles.
32. Analytical Sensitivity
Analytical sensitivity describes how well a system can detect a target at low concentration or abundance.
Important metrics can include:
- Limit of detection
- Limit of quantification
- Detection probability
- Variant allele fraction threshold
- Copies per reaction
- Copies per mL
33. Analytical Specificity
Specificity is influenced by:
- Primer design
- Probe design
- Target selection
- Sequence similarity
- Cross-reactivity
- Contamination
- Bioinformatics filtering
A molecular assay can have excellent sensitivity but poor clinical usefulness if specificity is inadequate.
34. Precision and Reproducibility
Precision should be evaluated at clinically relevant concentrations.
For quantitative assays, laboratories should assess:
- Repeatability
- Within-run precision
- Between-run precision
- Between-day precision
- Between-operator precision
- Between-lot performance
35. Molecular Method Verification and Validation
Before a molecular method is introduced for clinical use, the laboratory must establish that the method performs appropriately for its intended use and local workflow.
Depending on the assay, evaluation may include:
- Accuracy
- Precision
- Analytical sensitivity
- Analytical specificity
- LoD
- Linearity or reportable range where applicable
- Carryover
- Interference
- Cross-reactivity
- Specimen stability
- Reference or expected results where appropriate
NGS requires additional evaluation of sequencing and bioinformatics performance. FDA guidance specifically addresses design and analytical validation considerations for NGS-based IVDs.
36. Contamination and Carryover in Molecular Laboratories
Molecular laboratories must take contamination seriously because even a small amount of amplified nucleic acid can produce a false-positive result.
When evaluating a platform, ask:
- Is the system closed?
- Are reaction vessels opened after amplification?
- How are waste products handled?
- Are aerosol-resistant tips required?
- How are work areas separated?
- What decontamination procedures are required?
37. Automation in Molecular Diagnostics
Automation can occur at several levels.
| Automation level | Examples |
|---|---|
| Pre-analytical | Barcode reading, aliquoting, sorting |
| Extraction | Automated DNA/RNA purification |
| Amplification | Automated PCR setup and thermal cycling |
| Sequencing | Automated library loading and sequencing |
| Bioinformatics | Automated pipelines and variant calling |
| Post-analytical | Autoverification, reporting and LIS integration |
38. Throughput: Advertised vs Real-World
A manufacturer may quote an impressive maximum throughput. That number should not be considered the same as clinical laboratory productivity.
Real-world throughput is influenced by:
- Sample loading
- Extraction time
- Batch size
- Assay complexity
- Reagent preparation
- Repeat testing
- Invalid rates
- Maintenance
- QC
- Manual intervention
- Data analysis
Clinical reportable samples ÷ total operational time
For NGS, throughput must also consider the number of reportable samples per run, not simply the number of reads generated.
39. TAT: Think From Sample Receipt to Report
A molecular instrument may have a short analytical run time but still produce a long overall turnaround time.
Total TAT can include:
This is especially important for NGS, where library preparation, sequencing and bioinformatics can contribute substantially to the total turnaround time.
40. Cost Per Reportable Result
Instrument price alone is a poor way to compare molecular platforms.
A better calculation is:
Include:
- Instrument depreciation
- Reagents
- Extraction consumables
- Controls
- Calibrators/reference materials
- Plasticware
- Library preparation
- Sequencing reagents
- Bioinformatics
- Software licences
- Maintenance
- Staff time
- Repeat testing
- Invalid runs
- Waste
41. Closed Cartridge vs Open Workflow Economics
A closed cartridge can simplify the workflow but may have a higher per-test consumable cost.
An open workflow can provide lower reagent costs and greater flexibility but usually requires greater technical expertise.
| Economic factor | Closed system | Open workflow |
|---|---|---|
| Hands-on time | Usually lower | Usually higher |
| Flexibility | Lower | Higher |
| Menu expansion | Vendor dependent | Potentially easier |
| Consumable cost | Can be higher | Potentially lower |
| Technical expertise | Lower requirement | Higher requirement |
42. LIS and Middleware Connectivity
Molecular diagnostics generates more information than a simple positive/negative result.
A good system should support:
- Bidirectional LIS communication
- Barcode identification
- Sample tracking
- Result transmission
- Instrument flags
- QC information
- Audit trails
- Autoverification
- Variant-report integration where applicable
43. Data Management and Storage
NGS introduces significant data-management requirements.
Laboratories should plan for:
- Raw sequencing data
- Processed data
- Variant files
- Interpretation records
- Quality metrics
- Report archives
- Backup
- Cybersecurity
- Long-term retention
Data infrastructure can therefore become a significant component of the total cost of an NGS laboratory.
44. Cybersecurity and Software
As molecular analyzers become connected systems, cybersecurity becomes part of laboratory instrument management.
Consider:
- User authentication
- Access control
- Audit trails
- Software updates
- Network security
- Data encryption
- Backup
- Remote service access
45. Major Molecular Diagnostics Technology Providers
The molecular diagnostics landscape includes companies focused on PCR, sequencing, extraction, automation and integrated diagnostic workflows.
| Company / ecosystem | Major technology areas |
|---|---|
| Roche Diagnostics | PCR, molecular diagnostics, automation and sequencing-related technologies |
| Abbott | Real-time PCR and integrated molecular diagnostics |
| Hologic | Molecular diagnostics and automated amplification platforms |
| Danaher / Cepheid | Rapid cartridge-based molecular diagnostics |
| QIAGEN | Sample preparation, PCR and molecular workflows |
| bioMĂ©rieux | Molecular infectious-disease diagnostics and integrated systems |
| Thermo Fisher Scientific | PCR, dPCR, NGS and companion-diagnostic technologies |
| Illumina | NGS sequencing platforms |
| Oxford Nanopore | Long-read sequencing technologies |
| Bio-Rad | PCR and digital PCR technologies |
| Indian molecular diagnostics companies | PCR, extraction, kits, POC and selected NGS solutions |
Manufacturer portfolios and regulatory status vary by country and change over time. Individual platform claims should therefore be verified against the manufacturer's current documentation and applicable regulatory database before procurement.
46. Indian Molecular Diagnostics Landscape
India has developed a growing molecular diagnostics ecosystem that includes both multinational and domestic manufacturers.
Indian companies are active in areas including:
- RT-PCR kits
- PCR instruments
- Nucleic-acid extraction
- Automation
- Point-of-care molecular diagnostics
- NGS assays
- Genetic testing
For example, Genes2Me describes a portfolio spanning RT-PCR instruments and kits, nucleic-acid extraction, automation, point-of-care testing and NGS clinical assays.
47. PCR vs NGS: Which Should a Laboratory Choose?
| Question | PCR | NGS |
|---|---|---|
| Number of targets | Usually focused | Potentially very large |
| TAT | Usually faster | Usually longer |
| Data volume | Relatively small | Very large |
| Cost/sample | Usually lower | Generally higher |
| Known target | Excellent | Possible but may be unnecessary |
| Broad variant discovery | Limited | Major advantage |
| Bioinformatics | Usually limited | Essential for many applications |
Ask which technology best answers the clinical question at the required sensitivity, turnaround time and cost.
48. When PCR Is the Better Choice
- Known target
- Rapid diagnosis required
- High-volume routine testing
- Limited number of targets
- Established validated assay
- Lower cost required
49. When NGS Is the Better Choice
- Many genes need to be assessed simultaneously
- Broad genomic profiling is required
- Multiple variant classes need investigation
- Rare disease evaluation requires broad sequencing
- Oncology profiling requires a large genomic panel
- Discovery of previously unknown variants is important
50. Platform Selection: The Questions That Matter
Clinical menu
- What tests will actually be performed?
- How many samples per day?
- Which specimen types?
- Which targets?
- What is the expected growth?
Analytical performance
- What is the LoD?
- What is the analytical specificity?
- What is the invalid rate?
- What is the reproducibility?
- How are inhibitors handled?
Workflow
- How much hands-on time?
- How many steps are manual?
- Is extraction integrated?
- Can samples be loaded continuously?
- Can STAT samples be accommodated?
Economics
- Capital cost?
- Cost per test?
- Maintenance cost?
- Software cost?
- Annual reagent commitment?
- Cost of invalid/repeat testing?
51. Molecular Platform Evaluation Using Real Patient Samples
Vendor demonstrations should not rely exclusively on ideal specimens.
A laboratory evaluation should include representative and difficult samples where appropriate:
- Low-positive samples
- High-positive samples
- Negative samples
- Inhibitory specimens
- Different specimen matrices
- Previously characterized positive samples
- Known challenging variants
- Low-level targets
The purpose is to understand how the platform behaves under actual laboratory conditions.
52. Molecular Platform Verification Checklist
| Parameter | Evaluation |
|---|---|
| Accuracy | Compare with reference/comparator method |
| Precision | Repeat testing at clinically relevant levels |
| LoD | Determine detection capability according to intended use |
| Specificity | Evaluate cross-reactivity and interference |
| Extraction | Assess yield and reproducibility |
| Inhibition | Evaluate internal-control behavior |
| Carryover | High-positive to negative sequence testing |
| Stability | Specimen/reagent stability as applicable |
| Workflow | Hands-on time and TAT |
| Connectivity | LIS and middleware verification |
53. Common Mistakes When Buying Molecular Platforms
- Choosing based only on instrument price
- Comparing advertised throughput instead of reportable throughput
- Ignoring extraction quality
- Ignoring invalid rates
- Ignoring manual hands-on time
- Not assessing reagent dependency
- Ignoring service support
- Ignoring software and bioinformatics costs
- Failing to test difficult specimens
- Underestimating contamination-control requirements
- Ignoring future menu expansion
- Not planning backup capacity
54. The Importance of Backup Capacity
A molecular laboratory should have a contingency plan for instrument failure.
Ask:
- Is there a second analyzer?
- Can testing be transferred to another platform?
- Are compatible reagents available?
- What is the expected service response?
- What happens to urgent samples?
- Can samples be referred temporarily?
55. LabDecoded Molecular Platform Scorecard
LabDecoded can use a standardized scoring framework when comparing molecular platforms.
| Category | Suggested Weight |
|---|---|
| Analytical performance | 20% |
| Clinical menu | 15% |
| Workflow / automation | 15% |
| Turnaround time | 10% |
| Reliability / uptime | 10% |
| Connectivity / software | 10% |
| Cost per reportable result | 10% |
| Service / support | 5% |
| Future scalability | 5% |
Technology + Analytical Performance + Workflow + Clinical Utility + Connectivity + Economics + Reliability + Scalability
56. The Future of Molecular Diagnostics
Molecular diagnostics is moving toward greater integration.
Important developments include:
- Sample-to-answer systems
- Higher multiplexing
- Digital PCR
- Faster sequencing
- Long-read sequencing
- Automated extraction and library preparation
- AI-assisted bioinformatics
- Liquid biopsy
- Minimal residual disease testing
- Companion diagnostics
- Point-of-care molecular testing
- Cloud-based analysis
- Integrated laboratory automation
The direction of travel is clear: the molecular laboratory is becoming an integrated ecosystem rather than a room containing separate PCR and sequencing instruments.
57. The Molecular Laboratory of the Future
The future platform may therefore be evaluated less as an individual analyzer and more as an end-to-end diagnostic ecosystem.
58. Frequently Asked Questions
What is a molecular diagnostics platform?
A molecular diagnostics platform is a system used to detect, quantify, characterize or sequence DNA, RNA or other molecular targets from clinical specimens.
What is the difference between PCR and NGS?
PCR generally focuses on specific predefined targets, whereas NGS can interrogate many genomic regions simultaneously and generate much larger datasets.
Is digital PCR better than qPCR?
Not universally. Digital PCR can offer advantages for certain low-level or precise quantification applications, while qPCR remains highly effective for many routine molecular tests.
What is a sample-to-answer molecular system?
It is a platform that integrates several steps such as sample preparation, nucleic-acid extraction, amplification and detection into a largely automated workflow.
Why is nucleic-acid extraction important?
Poor extraction can reduce target recovery or introduce inhibitors, causing false-negative or unreliable molecular results.
What should be compared when purchasing a PCR analyzer?
Compare analytical performance, assay menu, throughput, TAT, sample capacity, multiplexing, automation, contamination control, connectivity, reagent cost, service and total cost per reportable result.
What should be compared when purchasing an NGS platform?
Compare sequencing chemistry, read characteristics, throughput, run time, library preparation, coverage, data quality, bioinformatics, automation, software, clinical menu, cost and total turnaround time.
Can NGS replace PCR?
NGS can replace some targeted molecular workflows in selected applications, but PCR remains highly valuable for rapid, focused and cost-effective testing. The two technologies are complementary rather than universally interchangeable.
59. LabDecoded Internal Resources
Molecular diagnostics should be considered together with laboratory quality and analytical-performance principles. Explore related LabDecoded resources:
- Method Validation
- Method Verification
- Method Comparison
- Bland-Altman Plot
- Linearity Verification
- LoB / LoD / LoQ Calculator
- Carryover Study
- Measurement Uncertainty
- Quality Control in Clinical Laboratory
60. Explore the LabDecoded Lab Systems Section
- Clinical Chemistry Analyzers
- Immunoassay Analyzers
- Hematology Analyzers
- Coagulation Analyzers
- Urinalysis Analyzers
- HbA1c Analyzers
- Laboratory Automation
61. What LabDecoded Will Cover Next
The molecular diagnostics pillar can become the entry point to a complete molecular-platform database.
- PCR Systems: Complete Guide
- Real-Time PCR Systems
- Multiplex PCR Platforms
- Digital PCR Systems
- NGS Platforms
- Short-Read vs Long-Read Sequencing
- Automated Nucleic-Acid Extraction Systems
- Sample-to-Answer Molecular Systems
- Molecular Analyzer Comparison
- PCR vs Digital PCR
- PCR vs NGS
- NGS Platform Comparison
- Individual Molecular Platform Reviews
- Molecular Diagnostics Manufacturers
62. Final LabDecoded Takeaway
Molecular diagnostics is no longer defined by PCR alone.
Today's molecular laboratory can combine targeted amplification, digital PCR, automated extraction, multiplex testing, next-generation sequencing, long-read sequencing, bioinformatics and laboratory automation.
The most appropriate platform depends on the clinical question, target, specimen, required sensitivity, turnaround time, workload, available expertise and economics.
For routine targeted testing, PCR may remain the most efficient technology. For highly sensitive quantitative applications, digital PCR can provide additional capabilities. For broad genomic interrogation, NGS offers a fundamentally different approach.
The best molecular platform is therefore not necessarily the most technologically advanced platform. It is the platform that provides the required clinical information with appropriate analytical performance, workflow efficiency, reliability and total cost.
0 Comments